Late-stage pipeline program, Anaphylm™ (epinephrine) Sublingual Film, remains on track for a near-term New Drug Application (NDA) submission to the FDAExpanded sales coverage for Libervant™ (diazepam) Buccal Film for patients between ages two to five with national retail distribution anticipated in the fourth quarter 2024Anticipates holding epinephrine prodrug technology investor day in the coming monthsFinishes the second quarter 2024 with cash and cash equivalents of approximately $90 million and reaffirm ...

WARREN, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the second quarter ended June 30, 2024 and provide an update on recent developments in its business after market close on Tuesday, August 6, 2024. Management will host a conference call for i ...

WARREN, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the second quarter ended June 30, 2024 and provide an update on recent developments in its business after market close on Tuesday, August 6, 2024. Management will host a conference call for ...

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Aquestive Therapeutics, Inc. (AQST) is a pharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 16.7% downward over the last 60 days.Central Garden & Pet Company (CENTA) is a consumer goods company. The Zacks Consensus Estimate for its current year earnings has been revised 5% downward over the last 60 days.LiveRamp Holdings, Inc. (RAMP) is a technology company.The Zacks Consensus Estimate ...

WARREN, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the Aquestive management team will participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism and host investor meetings on July 9, 2024. The forum will include panels exploring key therapeutic themes a ...

WARREN, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced its expected addition to the broad-market Russell 3000® and Russell 2000® Indexes at the conclusion of the 2024 Russell U.S. indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1, acc ...

WARREN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in The Citizens JMP Life Sciences Conference on May 13, 2024. The Aquestive management team will hold a fireside chat on May 13 at 11:30 am ET and will host investor meetings. A webcast of the fireside chat will b ...

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Bennett Watson – ICR Westwicke Investor Relations Dan Barber – Chief Executive Officer and President Ernie Toth – Chief Financial Officer Stephen Wargacki – Chief Science Officer Conference Call Participants David Amsellem – Piper Sandler Francois Brisebois – Oppenheimer Ram Selvaraju – H.C. Wainwright Gary Nachman – Raymond James Thomas Flaten – Lake Street Capital Markets Operator Good m ...

Advancing medicines. Solving problems. Improving lives. 1 First Quarter 2024 Earnings Supplemental Materials May 7, 2024 Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. 2 ® Disclaimer Certain statements in this presentation include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "anticipate," "plan," "expect," "estimate," "intend," "may," "will," or the negative o ...

Aquestive Therapeutics (AQST) reported $12.05 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 8.3%. EPS of -$0.17 for the same period compares to $0.11 a year ago. The reported revenue represents a surprise of -1.37% over the Zacks Consensus Estimate of $12.22 million. With the consensus EPS estimate being -$0.09, the EPS surprise was -88.89%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectatio ...